EOLS Q2 2020 Earnings — Evolus, Inc. Revenue & Financial Results | Market Cap Arena

EOLSEvolus, Inc.

$338M

Q2 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$8M+237.8% YoY

Gross Profit

$4M53.8% margin

Operating Income

-$13M-172.9% margin

Net Income

-$21M-270.6% margin

EPS (Diluted)

$-0.63

QoQ Revenue Growth

-25.6%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$15M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$195M

Total Liabilities

$151M

Stockholders' Equity

$44M

Cash & Equivalents

$30M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$2M	+237.8%
Gross Profit	$4M	$2M	+154.4%
Operating Income	-$13M	-$36M	+62.5%
Net Income	-$21M	-$38M	+43.8%